FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075906149> ?p ?o ?g. }

• W2075906149 endingPage "142" @default.
• W2075906149 startingPage "135" @default.
• W2075906149 abstract "Although, in southern Europe, there has been considerable experience in the treatment of visceral leishmaniasis (VL) in HIV-positive patients, the optimal therapy has yet to be established. Pentavalent antimony salts, free amphotericin B deoxycholate (ABD) and lipidic formulations of amphotericin B are the drugs most commonly used. Treatment with pentavalent antimonials requires daily injections for 28 days, is not well tolerated and leads to initial clinical cure in only 66% of the co-infected cases. Free ABD has to be given, intravenously, for just as long, has significant toxicity and leads to initial clinical cure in even fewer cases (62%). In a prospective, comparative trial, treatment of co-infected cases with a pentavalent antimonial was found to have similar efficacy and toxicity to treatment with free ABD. The duration of treatment and the associated toxicity may both be reduced by the use of lipidic formulations of amphotericin B. Anecdotal evidence and the results of non-randomized trials indicate that treatment with liposomal amphotericin B is highly effective. In a comparative trial, amphotericin B lipid complex was found to be not only as effective as a pentavalent antimonial but also better tolerated. At the moment, however, such lipidic formulations have only been tested against VL/HIV cases in Europe, not elsewhere in the world, and they remain very expensive. However successful the treatment in terms of initial clinical cure, almost all VL/HIV cases develop VL relapses. Although the data available on secondary prophylaxis are limited and often inconclusive, it appears that regular treatment with a pentavalent antimonial drug, liposomal amphothericin B or amphotericin B lipid complex can reduce the incidence of leishmanial relapses in HIV-positive patients with VL. The development of new regimens, use of new oral drugs (such as miltefosine) and the development of new antileishmanial drugs could all improve the treatment of HIV-related VL in the future." @default.
• W2075906149 created "2016-06-24" @default.
• W2075906149 creator A5060177825 @default.
• W2075906149 date "2003-10-02" @default.
• W2075906149 modified "2023-09-23" @default.
• W2075906149 title "Treatment of leishmaniasis in HIV-positive patients" @default.
• W2075906149 cites W1827183518 @default.
• W2075906149 cites W1835042769 @default.
• W2075906149 cites W1963926135 @default.
• W2075906149 cites W1964008976 @default.
• W2075906149 cites W1992129867 @default.
• W2075906149 cites W1995452347 @default.
• W2075906149 cites W1998877606 @default.
• W2075906149 cites W2000120329 @default.
• W2075906149 cites W2014662504 @default.
• W2075906149 cites W2020136924 @default.
• W2075906149 cites W2023998456 @default.
• W2075906149 cites W2029049300 @default.
• W2075906149 cites W2039163253 @default.
• W2075906149 cites W2048636029 @default.
• W2075906149 cites W2049702118 @default.
• W2075906149 cites W2063852433 @default.
• W2075906149 cites W2063982195 @default.
• W2075906149 cites W2071406018 @default.
• W2075906149 cites W2078133861 @default.
• W2075906149 cites W2094444526 @default.
• W2075906149 cites W2122247224 @default.
• W2075906149 cites W2133634376 @default.
• W2075906149 cites W2135100126 @default.
• W2075906149 cites W2148589496 @default.
• W2075906149 cites W2160455203 @default.
• W2075906149 cites W2315055132 @default.
• W2075906149 cites W2319572609 @default.
• W2075906149 doi "https://doi.org/10.1179/000349803225002606" @default.
• W2075906149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14678640" @default.
• W2075906149 hasPublicationYear "2003" @default.
• W2075906149 type Work @default.
• W2075906149 sameAs 2075906149 @default.
• W2075906149 citedByCount "68" @default.
• W2075906149 countsByYear W20759061492012 @default.
• W2075906149 countsByYear W20759061492013 @default.
• W2075906149 countsByYear W20759061492014 @default.
• W2075906149 countsByYear W20759061492015 @default.
• W2075906149 countsByYear W20759061492016 @default.
• W2075906149 countsByYear W20759061492017 @default.
• W2075906149 countsByYear W20759061492018 @default.
• W2075906149 countsByYear W20759061492021 @default.
• W2075906149 countsByYear W20759061492022 @default.
• W2075906149 crossrefType "journal-article" @default.
• W2075906149 hasAuthorship W2075906149A5060177825 @default.
• W2075906149 hasConcept C126322002 @default.
• W2075906149 hasConcept C141071460 @default.
• W2075906149 hasConcept C16005928 @default.
• W2075906149 hasConcept C203014093 @default.
• W2075906149 hasConcept C2776555147 @default.
• W2075906149 hasConcept C2778689377 @default.
• W2075906149 hasConcept C2779548794 @default.
• W2075906149 hasConcept C2779629538 @default.
• W2075906149 hasConcept C2780402444 @default.
• W2075906149 hasConcept C2909039274 @default.
• W2075906149 hasConcept C29730261 @default.
• W2075906149 hasConcept C535046627 @default.
• W2075906149 hasConcept C71924100 @default.
• W2075906149 hasConcept C90924648 @default.
• W2075906149 hasConcept C98274493 @default.
• W2075906149 hasConceptScore W2075906149C126322002 @default.
• W2075906149 hasConceptScore W2075906149C141071460 @default.
• W2075906149 hasConceptScore W2075906149C16005928 @default.
• W2075906149 hasConceptScore W2075906149C203014093 @default.
• W2075906149 hasConceptScore W2075906149C2776555147 @default.
• W2075906149 hasConceptScore W2075906149C2778689377 @default.
• W2075906149 hasConceptScore W2075906149C2779548794 @default.
• W2075906149 hasConceptScore W2075906149C2779629538 @default.
• W2075906149 hasConceptScore W2075906149C2780402444 @default.
• W2075906149 hasConceptScore W2075906149C2909039274 @default.
• W2075906149 hasConceptScore W2075906149C29730261 @default.
• W2075906149 hasConceptScore W2075906149C535046627 @default.
• W2075906149 hasConceptScore W2075906149C71924100 @default.
• W2075906149 hasConceptScore W2075906149C90924648 @default.
• W2075906149 hasConceptScore W2075906149C98274493 @default.
• W2075906149 hasIssue "sup1" @default.
• W2075906149 hasLocation W20759061491 @default.
• W2075906149 hasLocation W20759061492 @default.
• W2075906149 hasOpenAccess W2075906149 @default.
• W2075906149 hasPrimaryLocation W20759061491 @default.
• W2075906149 hasRelatedWork W2025822586 @default.
• W2075906149 hasRelatedWork W204048988 @default.
• W2075906149 hasRelatedWork W2040676363 @default.
• W2075906149 hasRelatedWork W2060138253 @default.
• W2075906149 hasRelatedWork W2083068805 @default.
• W2075906149 hasRelatedWork W2144136866 @default.
• W2075906149 hasRelatedWork W2147221460 @default.
• W2075906149 hasRelatedWork W2411080853 @default.
• W2075906149 hasRelatedWork W2781435413 @default.
• W2075906149 hasRelatedWork W2940893598 @default.
• W2075906149 hasVolume "97" @default.
• W2075906149 isParatext "false" @default.
• W2075906149 isRetracted "false" @default.

• next